Study Stopped
Terminée
Cerebral Impact of Cognitive Remediation for People Suffering From Schizophrenia
IMPACTRCS
1 other identifier
interventional
78
1 country
1
Brief Summary
Neurocognitive deficits are frequent with people suffering from schizophrenia. Unlike positive symptoms, cognitive deficits are not reduced with antipsychotic medication. They can be very disabling, especially for social and professional rehabilitation. Cognitive deficits can concern primary processes such as attention or more integrative processes. Social cognition is also massively altered. As a consequence, decision making is often altered with the presence of the 'jumping to conclusion' (JTC) phenomenon. People that jump to conclusion are making decisions without having the necessary information to be sure of their judgment. In addition, people suffering from schizophrenia also present differences in cerebral activity. For instance, the P300 involved in executive processes appears later and with a smaller amplitude. Many cognitive remediation programs have been created to overcome these deficits. Their efficiency has been proved. However, their effects on cerebral activity have not been studied extensively in literature, especially concerning decision making changes. The present project will use a cognitive remediation program centered on social decision making to test its efficiency on JTC and the potential changes in cerebral activity it can induce. This program, inspired by the SCIT (Social Cognition and Interaction Technique) will be based on 10 sessions (1 each week). Participants will be tested before and after remediation/control group with 3 experimental tasks. Cerebral activity will be measured with an EEG cap. They will also undergo a neuropsychological evaluation and a symptomatology evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable schizophrenia
Started Dec 2019
Typical duration for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 5, 2019
CompletedFirst Posted
Study publicly available on registry
July 26, 2019
CompletedStudy Start
First participant enrolled
December 17, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 17, 2023
CompletedFebruary 14, 2024
February 1, 2024
3.5 years
July 5, 2019
February 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Jumping to the conclusion
The primary outcome will be modification before and after intervention of the correct response percentage. It is obtained by measuring the amplitude of the waves P300 and N200 of the electroencephalogram.
12 weeks
Secondary Outcomes (2)
Warwick-Edinburg mental well-being (WEMWBS)
12 weeks
The positive and the negative symptoms (PANNS)
12 weeks
Study Arms (2)
Cognitive remediation arm
EXPERIMENTALParticipants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
Control group
ACTIVE COMPARATORParticipants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
Interventions
10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
Eligibility Criteria
You may qualify if:
- People suffering from schizophrenia given the DSM-5
- People aged from 18 to 45 years old
- French mother tongue
- Medicated with Aripiprazole
- Medication unchanged in the last month
- Stable symptomatology
- People consenting to the research.
You may not qualify if:
- Recent addiction (tabacco excluded)
- Neurologic disorders (vascular disorders, neurodegenerative disorders, infections…)
- Somatic medication having cerebral impact (such as corticoids)
- Pregnant women, guardianship people.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
centre de réhabilitation - Hôpital le Vinatier
Lyon, Rhône, 69006, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
FRANCK Nicolas, Professor
CH Le Vinatier
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- The participants don't know the select group.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 5, 2019
First Posted
July 26, 2019
Study Start
December 17, 2019
Primary Completion
June 13, 2023
Study Completion
June 17, 2023
Last Updated
February 14, 2024
Record last verified: 2024-02